Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for Retinal Degenerative Disease

Ocugen announced that the FDA granted orphan drug designation for its OCU400 gene therapy for the treatment of NR2E3 mutation-associated retinal degenerative disease. Inherited retinal diseases (IRDs) are caused by genetic mutations that are passed down within families and lead to visual impairment and blindness. OCU400 consists of adeno-associated virus serotype 5 capsid containing the gene for human Nuclear Hormone Receptor NR2E3 and is the first program that Ocugen is advancing based on its modifier gene therapy platform.

“We are very pleased to receive our first orphan drug designation for a gene therapy product from the FDA,” Shankar Musunuri, PhD, MBA, Chairman, Chief Executive Officer and Co-Founder of Ocugen, said in a company news release. “Unlike single-gene replacement approaches, which have shown great promise in rare retinal diseases despite being highly specific for a single condition, we believe OCU400 represents a powerful and broad means of treating a variety of genetically diverse IRDs with a single product. Our initial strategy is to develop OCU400 as a gene augmentation therapy for patients with IRDs caused by mutations in the NR2E3 gene. Orphan designation for this initial indication is not only a major milestone for our Modifier Gene Therapy Platform, it also marks the third product in Ocugen’s clinical pipeline to be granted orphan drug designation. Our other orphan drug candidates include OCU100 for retinitis pigmentosa and OCU300, which is currently in Phase 3 clinical trials for the treatment of ocular graft versus host disease and is the only product candidate to be granted orphan drug designation for this indication.”

In a mouse model of NR2E3 mutation, NR2E3 delivery to retinal cells reversed disease progression. Based on these encouraging results, Ocugen plans to initiate a phase 1/2a clinical study by 2020. Future opportunities for OCU400 include additional rare/orphan retinal diseases where local NR2E3 gene augmentation may effectively prevent disease progression, including Leber Congenital Amaurosis (LCA), retinitis pigmentosa, and other retinal degenerative diseases.

“It is gratifying that a clinical trial is being planned for this serious retinal disorder caused by NR2E3 mutations. It has been 30 years since we first identified this IRD and now is the time to move toward therapy,” Samuel G. Jacobson, MD, PhD, Professor of Ophthalmology of the University of Pennsylvania, said in the news release.

The FDA Office of Orphan Products Development grants orphan designation for novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including a seven-year period of U.S. marketing exclusivity, tax credits for clinical research costs, clinical research trial design assistance, the ability to apply for annual grant funding and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.